UnitedHealth Group Receives BofA Price Target Upgrade to $512

What happened

Bank of America raised its price target on UnitedHealth Group stock to $512, joining several other analysts who upgraded their targets following the company's second-quarter 2026 earnings release on July 16. UnitedHealth reported revenue of $112 billion and adjusted earnings per share of $6.38, significantly exceeding analyst expectations of $110.9 billion in revenue and $4.90 EPS. Net income surged 60.7% year-over-year to $5.5 billion. The company's medical care ratio improved to 86.7% from 89.4% a year earlier, reflecting better cost management and lower healthcare utilisation. Operating cash flow nearly doubled to $11.1 billion. Management raised full-year adjusted EPS guidance to $19.50–$20.00 from the previous forecast of more than $18.25, and announced plans to repurchase at least $5 billion of its shares in 2026, having already repurchased $4 billion through mid-July. Other firms also raised their targets, with UBS lifting its target to $490, KeyBanc to $475, and Truist Securities to $480.

Why it matters

The BofA price target upgrade and strong earnings signal renewed investor confidence in UnitedHealth's turnaround strategy after a challenging 2025 marked by elevated medical costs, regulatory scrutiny, and a major cyberattack on its Change Healthcare payment arm. The improved medical care ratio demonstrates the company's success in restructuring its business, exiting unprofitable contracts, and using artificial intelligence to improve operational efficiency. The $5 billion share repurchase programme reflects management's confidence in the company's financial strength and future prospects. However, CFO Wayne DeVeydt tempered optimism by warning that commercial insurance medical costs continue climbing faster than expected, with costs rising more than 11% in that segment. Management now expects full margin normalisation in commercial lines won't arrive until after 2027, creating a mixed outlook despite the strong headline numbers.

Bigger picture

UnitedHealth's results reflect broader trends in American healthcare, where insurers are navigating persistent cost pressures from an ageing workforce, post-pandemic pent-up demand, and expensive new specialty drugs. As the nation's largest health insurer with a market capitalisation of $386.95 billion, UnitedHealth's performance carries significant weight for the healthcare sector. The company has recovered strongly in 2026, with shares up 49.6% over the past 52 weeks and 28.1% year-to-date, significantly outperforming the broader market. The stock currently trades at 21.44 times forward earnings, above the sector median of 19.42 times. Competitors face similar challenges with Medicare Advantage rate pressures and regulatory scrutiny over claim denials. UnitedHealth's 19% denial rate for in-network claims in ACA plans and 13% prior authorisation rates for some Medicare Advantage services continue to draw regulatory attention. The company's recovery from the Change Healthcare cyberattack, which cost more than $2 billion in remediation and lost revenue, demonstrates operational resilience but also exposed vulnerabilities in its technology infrastructure.

What to watch

Investors should monitor whether the improved medical care ratio trends continue, particularly in the commercial insurance segment where costs remain elevated. The company's full-year guidance projects a medical care ratio of around 88.1% (plus or minus 25 basis points) and operating cash flow of $24 billion. Analysts expect EPS of $18.77 for fiscal 2026 (a 14.8% increase) and $21.04 in fiscal 2027 (a 12.1% increase). Key factors include the pace of margin normalisation in commercial lines, Medicare Advantage enrollment trends amid continued rate pressures from CMS, and the company's ability to sustain improvements at Optum Health, which reported operating income of $4 billion in Q2. Regulatory developments around drug pricing, antitrust scrutiny, and election-year healthcare policy shifts could also impact results. The execution of the $5 billion buyback programme and the company's dividend strategy, with the annualised dividend recently increased to $9.28 per share, will signal management's ongoing confidence.